The AZUR-1 data strengthen Jemperli's clinical profile and support ongoing regulatory reviews via Project Orbis. Monitor ESMO presentation for additional detail and any updates on label expansion timelines in ex-US markets.
Price Chart
Executive Summary
GSK announced positive interim results from the phase II AZUR-1 trial of Jemperli (dostarlimab) monotherapy in MSI-H/dMMR locally advanced rectal cancer, showing a 76% complete response rate with no recurrences after a median follow-up of more than two years. The data supported a recent US approval in this indication and will be presented at ESMO. This is a positive clinical update for a niche indication, but the addressable patient population is small (5-10% of rectal cancers) and the financial impact on GSK's overall revenue is limited.
Key Facts
- 76% of evaluable patients (110/144) achieved a complete response to Jemperli alone in the AZUR-1 phase II trial
- 68% (98/144) achieved a sustained clinical complete response for at least 12 months (cCR12) without surgery
- No disease recurrences reported among responders after a median follow-up of more than two years
- Data supported recent US approval of Jemperli in this indication
- AZUR-1 met its primary objective of demonstrating a clinically significant proportion of patients achieving cCR12
- Safety profile consistent with established profile; serious adverse reactions in 20% of patients, discontinuation in 3%
Financial Impact
Positive but limited to a niche indication; MSI-H/dMMR represents 5-10% of rectal cancers. No revenue or sales figures provided in the filing.
Risk Factors
- Single-arm phase II trial with no comparator arm; confirmatory data may be needed
- Addressable patient population is small (5-10% of rectal cancers), limiting peak revenue potential
- Competing PD-1 inhibitors (e.g., Keytruda) already approved in MSI-H solid tumors
- Regulatory reviews outside the US are ongoing and outcomes are uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009130 |
| Document: 0001654954-26-009130-index-headers.html | 0001654954-26-009130 |
| Document: 0001654954-26-009130-index.html | 0001654954-26-009130 |
| Document: 0001654954-26-009130.txt | 0001654954-26-009130 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $51.15 | awaiting T+1 | — | $51.21 (+0.12%) |
Oct 26, 2026 today | 6-K | $50.99 | awaiting T+1 | — | $51.21 (+0.43%) |
Oct 26, 2026 1d ago | 6-K | $51.11 | awaiting T+1 | — | $51.21 (+0.20%) |
Oct 26, 2026 1d ago | 6-K | $50.83 | awaiting T+1 | — | $51.21 (+0.75%) |
Oct 21, 2026 6d ago | 6-K | $50.02 $51.21 | ▲ +2.38% | ▲ +3.56% | $51.21 (+2.38%) |
Oct 19, 2026 7d ago | 6-K | $49.46 $50.63 | ▲ +2.37% | ▲ +2.03% | $51.21 (+3.54%) |
Oct 19, 2026 8d ago | 6-K | $49.46 $50.63 | ▲ +2.37% | ▲ +2.03% | $51.21 (+3.54%) |
Oct 15, 2026 11d ago | 6-K | $49.02 $49.51 | ▲ +1.00% | ▲ +2.11% | $51.21 (+4.47%) |
Oct 14, 2026 12d ago | 6-K | $47.87 $49.02 | ▲ +2.40% | ▲ +2.12% | $51.21 (+6.98%) |
Oct 13, 2026 13d ago | 6-K | $46.27 $47.87 | ▲ +3.46% | ▲ +4.54% | $51.21 (+10.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers